Download PDF
CC BY-NC-ND 4.0 · Phlebologie 1998; 27(03): 27-34
DOI: 10.1055/s-0038-1639018
Original Article
Schattauer GmbH

Leitlinie[*]: Sklerosierungsbehandlung der Varikose

(ICD 10: I83.0, I83.1, I83.2, I83.9)
E. Rabe
1   Department of Dermatology, University of Bonn
,
F. Pannier
1   Department of Dermatology, University of Bonn
,
H. Gerlach
2   Department of Dermatology, University of Mannheim
,
F. X. Breu
3   Department of Dermatology, University of Rottach-Egern
,
S. Guggenbichler
4   Department of Dermatology, University of München
,
J. C. Wollmann
5   Department of Dermatology, University of Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden
› Author Affiliations
Further Information

Publication History

Eingegangen: 22 November 2007



Publication Date:
06 March 2018 (online)

    Permissions and Reprints

Leitlinien sind systematisch erarbeitete Empfehlungen, um den Kliniker und den Praktiker bei Entscheidungen über die angemessene Versorgung der Patienten im Rahmen spezifischer klinischer Umstände zu unterstützen.

Leitlinien gelten für „Standardsituationen“ und berücksichtigen die aktuellen, zu den entsprechenden Fragestellungen zur Verfügung stehenden, wissenschaftlichen Erkenntnisse. Leitlinien bedürfen der ständigen Überprüfung und eventuell der Änderung auf dem Boden des wissenschaftlichen Erkenntnisstandes und der Praktikabilität in der täglichen Praxis. Durch die Leitlinien soll die Methodenfreiheit des Arztes nicht eingeschränkt werden. Ihre Beachtung garantiert nicht in jedem Fall den diagnostischen und therapeutischen Erfolg. Leitlinien erheben keinen Anspruch auf Vollständigkeit. Die Entscheidung über die Angemessenheit der zu ergreifenden Maßnahmen trifft der Arzt unter Berücksichtigung der individuellen Problematik.

* Diese Leitlinie wurde im Auftrag der Deutschen Gesellschaft für Phlebologie (DGP) ausgearbeitet, vom Vorstand und im wissenschaftlichen Beirat der DGP am 15.06.2001 verabschiedet, am 26.09.2007 novelliert und ersetzt die Vorversion vom 12.05.2003 (75). Diese Leitlinie berücksichtigt den aktuellen Stand der Literatur, aber nicht die in jedem Fall unterschiedlichen Zulassungsbestimmungen für die verschiedenen Pharmaka. Gültigkeit: bis 31.12.2010


 

  • Literatur

  • 1 Alos J, Carreno P, Lopez JA, Estadella B, Serra-Prat M, Marinel-Lo J. Efficacy and safety of sclerotherapy using Polidocanol foam: A controlled clinical trial. Eur J Vasc Endovasc Surg 2006; 31,1: 101-107.
    Google Scholar
  • 2 Baccaglini U, Spreafico G, Castoro C, Sorrentino P. Consensus Conference on Sclerotherapy or Varicose Veins of the Lower Limbs. Phlebology 1997; 12: 2-16.
    CrossrefGoogle Scholar
  • 3 Baccaglini U, Stemmer R, Partsch U. Internationale Fragebogenaktion zur Praxis der Verödungsbehandlung. Phlebologie 1997; 26: 129-142.
    Google Scholar
  • 4 Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. Dermatol Surg 2004; 20: 6-12.
    Google Scholar
  • 5 Benigni JP. Sclérothérapieàlamousse et migraines à aura. Phlébologie 2005; 58,4: 323-324.
    Google Scholar
  • 6 Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg 2000; 26: 535-542.
    CrossrefPubMedGoogle Scholar
  • 7 Bergan JJ, Pascarella L, Mekenas L. Venous disorders: Treatment with sclerosant foam. J Cardiovasc Surg 2006; 47,1: 9-18.
    Google Scholar
  • 8 Breu FX, Guggenbichler S. European consensus meeting on foam sclerotherapy. April, 4–6, 2003, Tegernsee, Germany. Dermatol Surg 2004; 30,5: 709-717.
    Google Scholar
  • 9 Breu FX, Guggenbichler Wollmann JC. 2nd European Consensus Meeting on Foam Sclerotherapy, 28 –30April 2006, Tegernsee, Germany. Vasa 2008; 37 Suppl (71) 1-32.
    PubMedGoogle Scholar
  • 10 Breu FX, Marshall M. Sklerotherapie mit Polidocanol in einer angiologisch-phlebologischen Spezialpraxis. Prospektive und retrospektive Erhebung über Ergebnisse und Komplikationen. Phlebologie 2003; 32: 76-80.
    Article in Thieme ConnectGoogle Scholar
  • 11 Breu FX, Partsch B. Reversible neurologische Komplikationen bei der Schaum-Sklerotherapie. Phlebologie 2006; 3: 115-116.
    Article in Thieme ConnectGoogle Scholar
  • 12 Brodersen JP. Catheter-assisted vein sclerotherapy: A new approach for sclerotherapy of the greater saphenous vein with a double-lumen balloon catheter. Dermatol Surg 2007; 33,4: 469-475.
    Google Scholar
  • 13 Bullens-Goessens YIJM, Mentink LF, Nelemans PJ, Van Geest AJ, Veraart JCJM. Ultrasound-guided sclerotherapy of the insufficient short saphenous vein. Phlebologie 2004; 33,3: 89-91.
    Article in Thieme ConnectGoogle Scholar
  • 14 Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera Jr J, Garcia-Olmedo MA, Sierra A, Lloret P. et al. Ultrasound-guided injection of Polidocanol microfoam in the management of venous leg ulcers. ArchDermatol 2004; 140: 667-673.
    Google Scholar
  • 15 Cavezzi A, Frullini A, Ricci S, Tessari L. Treatment of varicose veins by foam sclerotherapy: Two clinical series. Phlebology 2002; 17: 13-18.
    CrossrefGoogle Scholar
  • 16 Ceulen RPM, Bullens-Goessens YIJM, Pi-Van De Venne SJA. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% Polidocanol foam: Results of a randomized controlled trial with 1-year follow-up. DermatolSurg 2007; 33,3: 276-281.
    Google Scholar
  • 17 Coleridge Smith PD. Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006; 32,5: 577-583.
    Google Scholar
  • 18 Conrad P, Malouf GM, Stacey MC. The Australian Polidocanol (Aethoxysklerol) study. Results at 2 years. Dermatol Surg 1995; 21: 334-336.
    PubMedGoogle Scholar
  • 19 De Waard MM, Der Kinderen DJ. Duplex ultrasonography-guided foam sclerotherapy of incompetent perforator veins in a patient with bilateral venous leg ulcers. Dermatol Surg 2005; 31,5: 580-583.
    Google Scholar
  • 20 Darke SG, Baker SJ. Ultrasound-guided foam sclerotherapy for the treatment of varicose veins. Br J Surg 2006; 8: 969-974.
    Google Scholar
  • 21 Drake LA, Dinehart SM, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ. Guidelines of care for sclerotherapy treatment of varicose and teleangiectatic leg veins. J Am Acad Dermatol 1996; 34: 523-528.
    CrossrefPubMedGoogle Scholar
  • 22 Dover J, Sadick N, Goldman MP. The role of lasers and light sources in the treatment of leg veins. Derm Surg 1999; 25: 328-336.
    CrossrefPubMedGoogle Scholar
  • 23 Duffy DM. Cutaneous necrosis following sclero-therapy. J Anesthetic Dermatol Cosmetic Surg 1999; 1,2: 157-168.
    Google Scholar
  • 24 Einarsson E, Eklöf B, Neglén P. Sclerotherapy or surgery as treatment for varicose veins: A prospective randomized study. Phlebology 1993; 8: 22-26.
    CrossrefGoogle Scholar
  • 25 Fegan WG. Continous compression technique of injecting varicose veins. Lancet 1963; 2: 109-112.
    PubMedGoogle Scholar
  • 26 Feied CF. Deep vein thrombosis: The risks of sclerotherapy in hypercoagulable states. Sem Dermatol 1993; 12,2: 135-149.
    Google Scholar
  • 27 Feied CF, Jackson JJ, Bren TS, Bond OB, Fernando CE, Young VC, Hashemiyoon RB. Allergic reactions to polidocanol for vein sclerosis. J Dermatol Surg Oncol 1994; 20: 466-468.
    CrossrefPubMedGoogle Scholar
  • 28 Feuerstein W. Schwere anaphylaktische Reaktion auf Hydroxypolyaethoxydodecan. VASA 1973; 3,2: 292-294.
    Google Scholar
  • 29 Fisher DC, Fisher EA, Budd JH. et al. The incidence of patent foramen ovale in 1000 consecutive patients. Chest 1995; 107,6: 1504-1509.
    Google Scholar
  • 30 Fisher DA. Regarding extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg 2000; 26,11: 1081.
    Google Scholar
  • 31 Flückiger P. Nicht-operative retrograde Varicenverödung mit Varisylschaum. Schweiz Med Wochenschr 1956; 48: 1368-1370.
    Google Scholar
  • 32 Forlee MV, Grouden M, Moore DJ. et al. Strokeafter varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43,1: 162-164.
    Google Scholar
  • 33 Frullini A, Cavezzi A. Ultrasound guided sclerotherapy in the treatment of long saphenaous vein insufficiency. Vasomed 1999; 11 Suppl (01) 8.
    Google Scholar
  • 34 Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectasases: History and analysis of safety and complications. Derm Surg 2002; 28: 11-15.
    PubMedGoogle Scholar
  • 35 Geerts WH, Pineo GF, Heit JA, Bergqvist D. et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
    CrossrefPubMedGoogle Scholar
  • 36 Georgiev M.. Post sclerotherapy hyperpigmentations. J Dermatol Surg Oncol 1993; 19: 649-652.
    CrossrefPubMedGoogle Scholar
  • 37 Geukens J, Rabe E, Bieber T. Embolia cutis medicamentosa of the foot after sclerotherapy. Eur J Dermatol 1999; 9: 132-133.
    PubMedGoogle Scholar
  • 38 Goldman PM, Beaudoing D, Marley W, Lopez L, Butie A. Compression in the treatment of leg teleangiectasia: A preliminary report. J Dermatol Surg Oncol 1990; 16: 322-325.
    CrossrefPubMedGoogle Scholar
  • 39 Goldmann PM, Bergan JJ, Guex JJ. Sclerotherapy–Treatment of varicose veins and telangiectatic leg veins. 4th Ed. Philadelphia:: Mosby Elsevier; 2007
    Google Scholar
  • 40 Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting and hyperpigmentation following sclerotherapy. Dermatol Surg 1995; 21: 19-29.
    CrossrefPubMedGoogle Scholar
  • 41 Grondin L, Young R, Wouters L. Sclérothérapie ècho-guidée et sécurité: Comparison des techniques. Phlebologie 1997; 50,2: 241-245.
    Google Scholar
  • 42 Guex JJ. Ultrasound guided sclerotherapy (USGS) for perforating veins. Hawaii Med J 2000; 59,6: 261-262.
    Google Scholar
  • 43 Guex JJ, Allaert F-A, Gillet J-L. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31,2: 123-128.
    Google Scholar
  • 44 Hamel-Desnos C, Desnos P, Wollmann JC. et al. Evaluation of the efficacy of Polidocanol in the form of foam compared with liquid form in sclerotherapy of the long saphenous vein: Initial results. Dermatol Surg 2003; 29,12: 1170-1175.
    Google Scholar
  • 45 Hamel-Desnos C, Ouvry P, Benigni JP, Boitelle G, Schadeck M, Desnos P, Allaert FA. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenousvein: a randomised, double-blind trial with 2year-follow-up. „The 3/1 Study“. Eur J Vasc Endovasc Surg 2007; 34: 723-729.
    CrossrefPubMedGoogle Scholar
  • 46 Hamel-Desnos C, Ouvry P, Desnos P, Escalard JM, Allaert FA. Sclérothérapie et thrombophilie: Démarche pour un consensus dans la sclérothérapie chez les thrombophiles. Phlébologie 2003; 56: 165-169.
    Google Scholar
  • 47 Henriet JP. One year experiencewith sclerotherapy of reticular veins and telangiectases using polidocanol foam in daily routine: Feasibility results, complications. Phlébologie 1997; 50,3: 355-360.
    Google Scholar
  • 48 Hertzman PA, Owens R. Rapid healing of chronic venous ulcers following ultrasound-guided foam sclerotherapy. Phlebology 2007; 22,1: 34-39.
    Google Scholar
  • 49 Hohlbaum G. Überiatrogene Schäden bei der Varizensklerosierung. In: Staubesand J, Schöpf E. (Hrsg). Neuere Aspekte der Sklerosierungstherapie. Berlin, Heidelberg:: Springer; 1990: 70-81.
    CrossrefGoogle Scholar
  • 50 Hübner K. Ambulante Therapie der Stammvarikose mittels Krossektomie und Sklerotherapie-ein Beitrag aus der Praxis des niedergelassenen Phlebologen. Phlebologie 1991; 20: 104-108.
    Google Scholar
  • 51 Kahle B. Effizienz der Sklerosierungstherapie von Besenreisern. Eine prospektive, randomisierte, doppelblinde, placebokontroliierte Studie. Vasomed 2006; 18,4: 148.
    Google Scholar
  • 52 Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins –a prospective, blinded placebo controlled study. Dermatol Surg 2004; 30: 723-728.
    PubMedGoogle Scholar
  • 53 Kakkos SK, Bountouroglou DG, Azzam M. et al. Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: Immediate results. J Endovasc Ther 2006; 13,3: 357-364.
    Google Scholar
  • 54 Kern P, Ramelet AA, Wütschert R. et al. Single-blind, randomized study comparing Chromated Glycerin, Polidocanol solution and Polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg 2004; 3: 367-372.
    Google Scholar
  • 55 Kern P, Ramelet AA, Wütschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins. A randomized controlled study. J Vas Surg 2007; 45,6: 1212-1216.
    Google Scholar
  • 56 Kersting E, Hornschuh B, Bröcker E-B. Embolia cutis medicamentosa nach Varizensklerosierung mit Polidocanol. Phlebologie 1998; 27: 55-57.
    Article in Thieme ConnectGoogle Scholar
  • 57 Kreussler:. Fachinformationen Aethoxysklerol 0,25% /0,5%/1%/2%Stand 06/2005, Aethoxysklerol 3% /4%. Stand 09/2005. Chemische Fabrik Kreussler &Co. GmbH,; Wiesbaden.:
    Google Scholar
  • 58 Künzelberger B, Pieck C, Altmeyer P, Stücker M. Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Derm Surg 2006; 32: 1410.
    PubMedGoogle Scholar
  • 59 Malouf GM. Ambulatory venous surgery versus sclerotherapy. Hawaii Med J 2000; 59: 248-249.
    PubMedGoogle Scholar
  • 60 Massay RA. Regarding the use of compression stockings after sclerotherapy. Dermatol Surg 1999; 25: 517.
    PubMedGoogle Scholar
  • 61 Mayer H, Brücke H. Zur Ätiologie und Behand-lung der Varizen der unteren Extremität. Chir Praxis 1957; 4: 521-528.
    Google Scholar
  • 62 McCoy S, Evans A, Spurrier N. Sclerotherapy for legtelangiectasia –ablinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg 1999; 25: 381-386.
    CrossrefPubMedGoogle Scholar
  • 63 Mc Donagh B. Comments on the use of post-sclerotherapy compression. Dermatol Surg 1999; 25,6: 519-521.
    Google Scholar
  • 64 Milleret R, Garandeau C. Sclérose des grandes veines saphénes à la mousse délivrée par cathéter écho-guidé sur veine vide: Alpha-technique –Bilan des 1.000 treatments. Phlébologie 2006; 59,1: 53-58.
    Google Scholar
  • 65 Monfreux A. Traitement sclérosant des troncs saphèniens et leurs collatèrales de gros calibre par la méthode mus. Phlébologie 1997; 50,3: 351-353.
    Google Scholar
  • 66 Morrison N, Cavezzi A, Bergan J, Partsch H. Regarding „stroke after varicose vein foam injection sclerotherapy“. J Vasc Surg 2006; 44,1: 224-225.
    Google Scholar
  • 67 Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan MedSurg 2007; 26,1: 22-28.
    Google Scholar
  • 68 Myers KA, Jolley D, Clough A. et al. Outcome of ultrasound-guided sclerotherapy for varicose veins: Medium-term results assessed by ultra-sound surveillance. Eur J Vasc Endovasc Surg 2007; 33,1: 116-121.
    Google Scholar
  • 69 Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: Effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20, 4: 643-649.
    CrossrefPubMedGoogle Scholar
  • 70 Oesch A, Stirnemann P, Mahler F. The acute ischemic syndrome of the foot after sclerotherapy of varicose veins. Schweiz Med Wochenschr 1984; 114: 1155-1158.
    PubMedGoogle Scholar
  • 71 Passariello F. Sclerosing foamand patent foramen ovale. The final report. In: Word Congress of the International Union of Phlebology; 2007 Jun 18–20; Kyoto, Japan. Int Angiol 2007; 26 (02) Suppl 1 87.
    Google Scholar
  • 72 Pradalier A, Vincent D, Hentschel V, Cohen-Jonathan AM, Daniel E. Allergie aux sclérosants des varices. Rev Fr Allergol 1995; 35,5: 440-443.
    Google Scholar
  • 73 Rabe E. (Hrsg). Grundlagen der Phlebologie. Köln:: Viavital; 2003
    Google Scholar
  • 74 Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): A randomised controlled multicentre clinical trial. Eur J Endovasc Vasc Surg (accepted for publication).;
    Google Scholar
  • 75 Rabe E, Pannier-Fischer F, Gerlach H, Breu FX. et al. Guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 2004; 30,5: 687-693.
    Google Scholar
  • 76 Rao J, Wildemore JK, Goldmann MP. Double-blind prospective comparative trial between foamed and liquid Polidocanol and Natrium Tetradecyl Sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg 2005; 31,6: 631-635.
    Google Scholar
  • 77 Ratanahirana H, Benigni JP, Bousser MG. Injection of Polidocanol foam(PF) in varicose veins as a trigger for attacks of migraine with visual aura. Cephalalgia 2003; 23: 850-851.
    CrossrefPubMedGoogle Scholar
  • 78 Reddy P, Wickers J, Terry T, Lamont P, Moller J, Dormandy JA. What is the correct period of bandaging following sclerotherapy?. Phlebology 1986; 1: 217-220.
    CrossrefGoogle Scholar
  • 79 Remy W, Vogt H-J, Borelli S. Embolia cutis medicamentosa-artige Hautnekrosen nach Sklerosierungsbehandlung. Phlebol Proktol 1978; 7: 67-72.
    Google Scholar
  • 80 Sadoun S, Benigni JP, Sica M. Étude prospective de l′efficacité de la mousse de sclérosant dans le traitement des varices tronculaires des membres inférieurs. Phlébologie 2002; 55: 259-262.
    Google Scholar
  • 81 Schadeck M. Duplex-kontrollierte Sklerosierungsbehandlung der Vena saphena magna. Phlebologie 1996; 25: 78-82.
    Google Scholar
  • 82 Schadeck M, Allaert FA. Résultatsàlong terme de la Sclérothérapie des Saphènes internes. Phlebologie 1997; 50,2: 257-262.
    Google Scholar
  • 83 Schadeck M. Sclérosedelapetite veine saphéne éviter les mauvais résultats?. Phlébologie 2004; 2: 165-169.
    Google Scholar
  • 84 Schultz-Ehrenburg U, Tourbier H. Doppler-kontrollierte Verödungsbehandlung der Vena saphena magna. Phlebol Proktol 1984; 13: 117-122.
    Google Scholar
  • 85 Seydewitz V, Staubesand J. Das ultrastrukturelle Substrat der Wirkung paravasal und intraarteriell applizierter Sklerosierungsmittel: Ein experimen-teller Beitrag zum Problem iatrogener Schäden nach Sklerotherapie. In: Staubesand J, Schöpf E. (Hrsg). Neuere Aspekte der Sklerosierungstherapie. Heidelberg: Springer; 1990: 40-65.
    CrossrefGoogle Scholar
  • 86 Sigg K. Neuere Gesichtspunkte zur Technikder Varizenbehandlung. Ther Umschau 1949; 6: 127-134.
    Google Scholar
  • 87 Snow V, Qaseem A, Barry P, Hornbake ER. et al. Management of venous thromboembolism: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007; 146: 204-210.
    CrossrefPubMedGoogle Scholar
  • 88 Stanley PRW, Bickerton DR, Campbell WB. Injection sclerotherapy for varicose veins – a comparison of materials for applying local compression. Phlebology 1991; 6: 37-39.
    CrossrefGoogle Scholar
  • 89 Stücker M, Reich S, Hermes N. et al. Safety and efficiency of perilesional sclerotherapy in leg ulcer patients with postthrombotic syndrome and/or oral anticoagulation with Phenprocoumon. JDDG 2006; 4,9: 734-738.
    Google Scholar
  • 90 Tazelaar DJ, Neumann HAM, de Roos KP. Long cotton wool rolls as compression enhancers in macro sclerotherapy for varicose veins. Dermatol Surg 1999; 25,1: 38-40.
    Google Scholar
  • 91 Tessari L, Cavezzi A, Frullini A. Preliminary experience with anew sclerosing foam in the treatment of varicose veins. DermatolSurg 2001; 27: 58-60.
    Google Scholar
  • 92 Vander Plas JPL, Lambers JC, van Wersch JW, Koehler PJ. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins. Lancet 1994; 343: 428.
    PubMedGoogle Scholar
  • 93 Villavicencio J, Pfeifer J, Lohr J, Goldman M, Cranley R, Spence R. Sclerotherapy for varicose veins: Practice guidelines and sclerotherapy procedures. In: Glovicki P, Yao J. (Eds). Handbook of venous disorders. London:: Chapmann & Hall Medical; 1996: 337-354.
    Google Scholar
  • 94 Vin F. Principes de la sclérothéraphiedes troncs saphènes internes. Phlebologie 1997; 50,2: 229-234.
    Google Scholar
  • 95 Wagdi P. Migräne und offenes Foramen Ovale: nur ein vorübergehender Hoffnungsschimmer?. Kardiovasc Med 2006; 9: 32-36.
    Google Scholar
  • 96 Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 1999; 25: 105-108.
    CrossrefPubMedGoogle Scholar
  • 97 Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: Hypertonics saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16: 800-804.
    CrossrefPubMedGoogle Scholar
  • 98 Wildenhues B. Endovenöse kathetergestützte Schaumsklerosierung. Phlebologie 2005; 34: 165-170.
    Article in Thieme ConnectGoogle Scholar
  • 99 Wollmann JC. Schaum –zwischen Vergangenheit und Zukunft. Vasomed 2002; 16 (01) 34-38.
    Google Scholar
  • 100 Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004; 30: 694-703.
    PubMedGoogle Scholar
  • 101 Wright D, Gobin JP, Bradbury AW, Coleridge-Smith P, Spoelstra H, Berridge D, Wittens CHA, Sommer A, Nelzen O, Chanter D. Varisolve European Phase III Investigators Group. Varisolve® polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006; 21,4: 180-190.
    Google Scholar
  • 102 Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg 2004; 30,5: 718-722.
    Google Scholar
  • 103 Yamaki T, Nozaki M, Sasaki K. Color duplex-guideds clerotherapy for the treatment of venous malformations. Dermatol Surg 2000; 26,4: 323-328.
    Google Scholar
  • 104 Zipper SG. Nervus peronäus-Schaden nachVarizensklerosierung mit Aethoxysklerol. Versicherungsmedizin 2000; 4: 185-187.
    Google Scholar